Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.
Modified vaccinia ankara virus vaccination provides long-term protection against nasal rabbitpox virus challenge
Jones, D. I., McGee, C. E., Sample, C. J., Sempowski, G. D., Pickup, D. J., & Staats, H. F. (2016). Modified vaccinia ankara virus vaccination provides long-term protection against nasal rabbitpox virus challenge. Clinical and Vaccine Immunology, 23(7), 648-651. https://doi.org/10.1128/CVI.00216-16
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Spatiotemporal trends in three smoothed overdose death rates in US counties, 2012-2020
Improving text classification with Boolean retrieval for rare categories
COVID-19 diagnosis and SARS-CoV-2 strain identification by a rapid, multiplexed, point-of-care antibody microarray